BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Teva
UBS
Healthtrust
Federal Trade Commission
Merck
Express Scripts
Moodys
Novartis
Chinese Patent Office

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,435,502

« Back to Dashboard

Which drugs does patent 8,435,502 protect, and when does it expire?

Patent 8,435,502 protects DIFFERIN and is included in one NDA.

This patent has seventeen patent family members in twelve countries.
Summary for Patent: 8,435,502
Title:Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers
Abstract: Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein.
Inventor(s): Mallard; Claire (Mougins, FR), Ferrara; Eve (Valbonne, FR)
Assignee: Galderma Research & Development (Biot, FR)
Application Number:13/171,872
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form; Process;

Drugs Protected by US Patent 8,435,502

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galderma Labs Lp DIFFERIN adapalene LOTION;TOPICAL 022502-001 Mar 17, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y TREATMENT OF ACNE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,435,502

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France05 09493Sep 16, 2005

Non-Orange Book US Patents Family Members for Patent 8,435,502

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,998,467 Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers ➤ Subscribe
8,709,392 Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,435,502

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 057866 ➤ Subscribe
Australia 2006290364 ➤ Subscribe
Brazil PI0617045 ➤ Subscribe
Canada 2622468 ➤ Subscribe
China 101262862 ➤ Subscribe
China 104013540 ➤ Subscribe
European Patent Office 1933827 ➤ Subscribe
France 2890861 ➤ Subscribe
Japan 2009508843 ➤ Subscribe
Japan 2012184258 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Boehringer Ingelheim
Harvard Business School
US Department of Justice
Covington
Chinese Patent Office
Novartis
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot